NEW
Cosentyx

Cosentyx Dosage/Direction for Use

secukinumab

Manufacturer:

Novartis

Distributor:

DKSH
Full Prescribing Info
Dosage/Direction for Use
Dosage regimen: Plaque psoriasis: The recommended dose is 300 mg by subcutaneous injection with initial dosing at weeks 0, 1, 2, 3 and 4 followed by monthly maintenance dosing.
Each 300 mg dose is given as two subcutaneous injections of 150 mg.
For some patients, a dosage of 150mg may be acceptable.
Psoriatic arthritis: The recommended dose is 150 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2, 3 and 4 followed by monthly maintenance dosing. Based on clinical response, the dose can be increased to 300 mg.
For patients who are anti-TNFα inadequate responders (IR) or patients with concomitant moderate to severe plaque psoriasis, the recommended dose is 300 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2, 3 and 4 followed by monthly maintenance dosing.
Each 300 mg dose is given as two subcutaneous injections of 150 mg.
Axial spondyloarthritis (axSpA): Ankylosing spondylitis (AS, radiographic axial spondyloarthritis): The recommended dose is 150 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2, 3 and 4 followed by monthly maintenance dosing. Based on clinical response, the dose can be increased to 300 mg.
Each 300 mg dose is given as two subcutaneous injections of 150 mg.
Non-radiographic axial spondyloarthritis (nr-axSpA): The recommended dose is 150 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2, 3, and 4 followed by monthly maintenance dosing.
Special populations:
Renal impairment/hepatic impairment: Cosentyx has not been studied specifically in these patient populations.
Pediatric patients: Safety and effectiveness in pediatric patients below the age of 18 years have not yet been established.
Geriatric patients (65 years or above): No dose adjustment is required.
Method of administration: Pre-filled pen: Cosentyx is administered by subcutaneous injection. If possible, areas of the skin that show psoriasis should be avoided as injection sites.
After proper training in subcutaneous injection technique, patients may self-inject Cosentyx if a physician determines that it is appropriate. However, the physician should ensure appropriate follow-up of patients. Patients should be instructed to inject the full amount of Cosentyx according to the instructions provided in the Patient Counselling Information. Comprehensive instructions for administration are given in the Patient Counselling Information.
Full instructions for use are provided in INSTRUCTIONS FOR USE AND HANDLING under Patient Counselling Information.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in